# US 2023/0265461 A1 · Compositions and methods for targeting, editing, or modifying genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265461 A1
- Document ID: US20230265461A1
- Status: Published application
- Kind: A1
- Application number: 18/189,201
- Filed: 2023-03-23
- Published: 2023-08-24
- Earliest claimed: 2021-02-25
- Assignees: Artisan Development Labs, Inc.
- Applicants: Artisan Development Labs, Inc.
- Inventors: Andrea BARGHETTI; Roland BAUMGARTNER; Tanya WARNECKE; Kurt MARSHALL; John SCHIEL; Alyssa Carlson
- Web page: https://patentgrep.com/patent/US20230265461A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/907: {in mammalian cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/351: Conjugate
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

## Claims

### Claim 1

A composition comprising a synthetic guide nucleic acid (gNA) comprising:
(i) a targeter nucleic acid comprising:
(a) a spacer sequence configured to hybridize with a target nucleotide sequence, and
(b) a targeter stem sequence; and
(ii) a modulator nucleic acid comprising:
(a) a modulator stem sequence complementary to the target stem sequence, and
(b) a 5′ sequence;
wherein the targeter stem sequence and the modulator stem sequence each comprise 4-10 nucleotides that base pair with each other, and
the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex,
wherein the targeter and modulator nucleic acids are separate polynucleotides, and
wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides or one or more modified internucleotide linkages at or near its 3′ end, at or near its 5′ end, or both, and wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first 10 nucleotides from the 5′ end.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the modulator nucleic acid comprises one to ten phosphorothioate modifications to internucleotide linkages.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the modulator nucleic acid comprises one to five phosphorothioate modifications to internucleotide linkages between one or more of the first five nucleotides from the 5′ end.

### Claim 5 (depends on 3)

The composition of claim 3 wherein the modulator nucleic acid comprises one to five 2′-O-methoxy modifications to nucleotides within the first five nucleotides from the 5′ end.

### Claim 6 (depends on 3)

The composition of claim 3 wherein the modulator nucleic acid comprises one to five fluoro modifications to nucleotides within the first five nucleotides from the 5′ end.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising the Type VA nucleic acid-guided nuclease complexed with the gNA.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the Type VA nucleic acid-guided nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of MAD1, MAD2, MAD3, MAD4, MAD5, MAD6, MAD7, MAD8, MAD9, MAD10, MAD11, MAD12, MAD13, MAD14, MAD15, MAD16, MAD17, MAD18, MAD19, or MAD20.

### Claim 10 (depends on 9)

The composition of claim 9 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to SEQ ID NO: 1.

### Claim 11 (depends on 8)

The composition of claim 8 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to an amino acid sequence of ART1, ART2, ART3, ART4, ART5, ART6, ART7, ART8, ART9, ART10, ART11, ART12, ART13, ART14, ART15, ART16, ART17, ART18, ART19, ART20, ART21, ART22, ART23, ART24, ART25, ART26, ART27, ART28, ART28, ART30, ART31, ART32, ART33, ART34, ART35, or ART11*.

### Claim 12

A method of editing a genome of a eukaryotic cell comprising
(I) delivering to the eukaryotic cell
(A) one or more synthetic guide nucleic acids (gNA), or polynucleotides encoding the one or more gNAs, comprising
(i) a targeter nucleic acid comprising:
(a) a spacer sequence configured to hybridize with a target nucleotide sequence, and
(b) a targeter stem sequence; and
(ii) a modulator nucleic acid comprising:
(a) a modulator stem sequence complementary to the target stem sequence, and
(b) a 5′ sequence;
wherein the targeter stem sequence and the modulator stem sequence each comprise 4-10 nucleotides that base pair with each other, and
the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex,
wherein the targeter and modulator nucleic acids are separate polynucleotides, and
wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides or one or more modified internucleotide linkages at or near its 3′ end, at or near its 5′ end, or both, and wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first 10 nucleotides from the 5′ end;
(B) the Type VA nucleic acid-guided nuclease, or polynucleotides encoding the nuclease;
wherein the gNA and the Type V nucleic acid-guided nuclease form a nucleic acid-guided nuclease complex; and
(II) contacting the genome with the nucleic acid-guided nuclease complex to form one or more strand breaks in the genome.

### Claim 13 (depends on 12)

The method of claim 12 wherein the modulator nucleic acid comprises one to ten phosphorothioate modifications to internudleotide linkages.

### Claim 14 (depends on 12)

The method of claim 12 wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.

### Claim 15 (depends on 14)

The method of claim 14 wherein the modulator nucleic acid comprises one to five phosphorothioate modifications to internucleotide linkages between one or more of the first five nucleotides from the 5′ end.

### Claim 16 (depends on 14)

The method of claim 14 wherein the modulator nucleic acid comprises one to five 2′-O-methoxy modifications to nucleotides within the first five nucleotides from the 5′ end.

### Claim 17 (depends on 14)

The method of claim 14 wherein the modulator nucleic acid comprises one to five fluoro modifications to nucleotides within the first five nucleotides from the 5′ end.

### Claim 18 (depends on 12)

The method of claim 12, wherein the Type VA nucleic acid-guided nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.

### Claim 19 (depends on 18)

The method of claim 18 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of MAD1, MAD2, MAD3, MAD4, MAD5, MAD6, MAD7, MAD8, MAD9, MAD10, MAD11, MAD12, MAD13, MAD14, MAD15, MAD16, MAD17, MAD18, MAD19, or MAD20.

### Claim 20 (depends on 19)

The method of claim 19 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to SEQ ID NO: 1.

### Claim 21 (depends on 18)

The method of claim 18 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to an amino acid sequence of ART1, ART2, ART3, ART4, ART5, ART6, ART7, ART8, ART9, ART10, ART11, ART12, ART13, ART14, ART15, ART16, ART17, ART18, ART19, ART20, ART21, ART22, ART23, ART24, ART25, ART26, ART27, ART28, ART28, ART30, ART31, ART32, ART33, ART34, ART35, or ART11*.

### Claim 22

A composition comprising a synthetic guide nucleic acid (gNA) comprising
(i) a targeter nucleic acid comprising:
(a) a spacer sequence configured to hybridize with a target nucleotide sequence, and
(b) a targeter stem sequence; and
(ii) a modulator nucleic acid comprising:
(a) a modulator stem sequence complementary to the target stem sequence, and
(b) a 5′ sequence;
wherein
(1) the targeter nucleic acid and modulator nucleic acids are separate polynucleotides,
(2) the predicted minimum free energy of hybridization of the targeter stem sequence and the modulator stem sequence, as determined by the RNAcofold Web Server, is between −10 and −4 kcal/mol, and
(3) the gNA is capable of binding to a CRISPR Type V nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the predicted minimum free energy of hybridization of the targeter stem sequence and the modulator stem sequence, as determined by the RNAcofold WebServer, is between −7 and −4 kcal/mol.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the targeter and modulator nucleic acids comprise a single polynucleotide.

### Claim 25 (depends on 22)

The composition of claim 22, wherein the targeter and modulator nucleic acids are separate polynucleotides.

### Claim 26 (depends on 22)

The composition of claim 22, wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides at or near its 3′ end, if present, at or near its 5′ end, if present, or both.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.

### Claim 28 (depends on 22)

The composition of claim 22, further comprising the Type VA nucleic acid-guided nuclease.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the amino acid sequence of the Type VA nucleic acid-guided nuclease is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.

### Claim 30

A method of editing a genome of a eukaryotic cell comprising
(I) delivering to the eukaryotic cell
(A) one or more synthetic guide nucleic acids (gNA), or polynucleotides encoding the one or more gNAs, comprising
(i) a targeter nucleic acid comprising:
(a) a spacer sequence configured to hybridize with a target nucleotide sequence, and
(b) a targeter stem sequence; and
(ii) a modulator nucleic acid comprising:
(a) a modulator stem sequence complementary to the target stem sequence, and
(b) a 5′ sequence;
wherein
(1) the targeter nucleic acid and modulator nucleic acids are separate polynucleotides,
(2) the predicted minimum free energy of the targeter stem sequence and the modulator stem sequence as determined by the RNAcofold Web Server is between −10 and −4 kcal/mol, and
(3) the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex;
(B) one or more Type VA nucleic acid-guided nucleases, or polynucleotides encoding the one or more nucleases; wherein the gNA and the Type V nucleic acid-guided nuclease form a nucleic acid-guided nuclease complex; and
(II) contacting the genome with the nucleic acid-guided nuclease complex to form one or more strand breaks in the genome.
